<DOC>
	<DOCNO>NCT00112502</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , temozolomide , work different way stop growth tumor cell , either kill cell stop dividing . Thalidomide may stop growth glioblastoma multiforme block blood flow tumor . Isotretinoin may help cell involve body 's immune response work well . Celecoxib may stop growth tumor cell block enzymes need cell growth . It yet know temozolomide-containing regimen effective treat glioblastoma multiforme . PURPOSE : This randomized phase II trial study eight different temozolomide-containing regimen compare well work treat patient undergone radiation therapy glioblastoma multiforme .</brief_summary>
	<brief_title>Temozolomide Alone Combination With Thalidomide and/or Isotretinoin and/or Celecoxib Treating Patients Who Have Undergone Radiation Therapy Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy adjuvant temozolomide ( TMZ ) alone combination thalidomide and/or isotretinoin and/or celecoxib , term 6-month progression-free survival , patient undergo radiotherapy supratentorial glioblastoma multiforme . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 8 treatment arm . - Arm I : Patients receive oral temozolomide daily day 1-7 15-21 . - Arm II : Patients receive temozolomide arm I oral thalidomide daily day 1-28 . - Arm III : Patients receive temozolomide arm I oral isotretinoin twice daily day 1-21 . - Arm IV : Patients receive temozolomide arm I oral celecoxib twice daily day 1-28 . - Arm V : Patients receive temozolomide arm I , thalidomide arm II , isotretinoin arm III . - Arm VI : Patients receive temozolomide arm I , thalidomide arm II , celecoxib arm IV . - Arm VII : Patients receive temozolomide arm I , isotretinoin arm III , celecoxib arm IV . - Arm VIII : Patients receive temozolomide arm I , thalidomide arm II , isotretinoin arm III , celecoxib arm IV . In arm , treatment repeat every 28 day 12 course absence disease progression unacceptable toxicity . Patient may receive additional course therapy discretion treat physician . After completion study treatment , patient follow least 30 day every 3 month thereafter . PROJECTED ACCRUAL : A total 180 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Isotretinoin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm supratentorial glioblastoma multiforme Must undergone biopsy OR subtotal gross total resection tumor Must complete postoperative ( postbiopsy ) radiotherapy within past 5 week No progressive disease radiotherapy PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 60100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Serum glutamate pyruvate transaminase ( SGPT ) &lt; 2 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 2 time ULN Bilirubin ≤ 1.5 mg/dL Renal blood urea nitrogen ( BUN ) ≤ 1.5 time ULN Creatinine ≤ 1.5 time ULN Immunologic No history allergic reaction attribute compound similar chemical biological composition celecoxib sulfonamides No asthma , urticaria , allergic reaction aspirin NSAIDs No active infection Gastrointestinal No inflammatory bowel disease No history peptic ulcer disease No gastrointestinal bleeding within past 3 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception 2 month study participation Fertile female patient randomize receive thalidomide must use effective doublemethod contraception ≥ 4 week , , ≥ 4 week completion study therapy Fertile male patient randomize receive thalidomide must use effective contraception ≥ 4 week completion study therapy No blood donation ( patient randomize receive thalidomide ) No history cancer except nonmelanoma skin cancer carcinoma situ cervix cancer complete remission patient complete therapy disease ≥ 3 year ago No disease would obscure toxicity dangerously alter drug metabolism ( e.g. , severe connective tissue disease ) No serious medical illness PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Prior temozolomide combination radiotherapy allow No prior concurrent chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics See Chemotherapy Surgery See Disease Characteristics No concurrent surgery Other No concurrent nonsteroidal antiinflammatory drug ( NSAIDs ) ( patient randomize receive celecoxib ) No concurrent investigational drug No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult glioblastoma</keyword>
</DOC>